Tom Wiggans

Tom brings over 40 years of experience in the biopharmaceutical industry, including over 25 years of chief executive leadership. He most recently served as Chief Executive Officer and Chairman of the Board of Directors of Dermira, Inc. which he co-founded in 2010, until its acquisition by Eli Lilly in 2020 for $1.1 billion. Prior to founding Dermira, Tom served as Chief Executive Officer and Chairman of the Board of Directors of Peplin, Inc. until its acquisition by LEO Pharma A/S in 2009. He also has served as Chief Executive Officer and Chairman of the Board of Directors of Connetics Corporation and in various other executive positions at CytoTherapeutics Inc. and Ares-Serono S.A. Tom began his career in the industry with Eli Lilly and Company.

Tom holds a B.S. in pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.